Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Correction: eEF-2 kinase is a critical regulator of Warbrug effect through controlling PP2A-A synthesis.

Cheng Y, Ren X, Yuan Y, Shan Y, Li L, Chen X, Zhang L, Takahashi Y, Yang JW, Han B, Liao J, Li Y, Harvey H, Ryazanov A, Robertson GP, Wan G, Liu D, Chen AF, Tao Y, Yang JM.

Oncogene. 2018 Jul 4. doi: 10.1038/s41388-018-0322-0. [Epub ahead of print]

PMID:
29973686
2.

Legacy effects of land use on soil nitrous oxide emissions in annual crop and perennial grassland ecosystems.

Abraha M, Gelfand I, Hamilton SK, Chen J, Robertson GP.

Ecol Appl. 2018 Jul;28(5):1362-1369. doi: 10.1002/eap.1745. Epub 2018 Jun 1.

PMID:
29856901
3.

Associative nitrogen fixation (ANF) in switchgrass (Panicum virgatum) across a nitrogen input gradient.

Roley SS, Duncan DS, Liang D, Garoutte A, Jackson RD, Tiedje JM, Robertson GP.

PLoS One. 2018 Jun 1;13(6):e0197320. doi: 10.1371/journal.pone.0197320. eCollection 2018.

4.

Measuring Spin Relaxation Rates Using Satellite Exchange NMR Spectroscopy.

Robertson GP, Odell B, Kuprov I, Dixon DJ, Claridge TDW.

Angew Chem Int Ed Engl. 2018 Jun 18;57(25):7498-7502. doi: 10.1002/anie.201801322. Epub 2018 Apr 14.

PMID:
29575317
5.

Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment.

Gowda R, Dinavahi SS, Iyer S, Banerjee S, Neves RI, Pameijer CR, Robertson GP.

Nanomedicine. 2018 Apr;14(3):863-873. doi: 10.1016/j.nano.2017.12.020. Epub 2018 Jan 6.

PMID:
29317343
6.

Moving Synergistically Acting Drug Combinations to the Clinic by Comparing Sequential versus Simultaneous Drug Administrations.

Dinavahi SS, Noory MA, Gowda R, Drabick JJ, Berg A, Neves RI, Robertson GP.

Mol Pharmacol. 2018 Mar;93(3):190-196. doi: 10.1124/mol.117.110759. Epub 2017 Dec 14.

PMID:
29242354
7.

Metastasis suppressor 1 (MTSS1) expression is associated with reduced in-vivo metastasis and enhanced patient survival in lung adenocarcinoma.

Taylor MD, Bollt O, Iyer SC, Robertson GP.

Clin Exp Metastasis. 2018 Feb;35(1-2):15-23. doi: 10.1007/s10585-017-9869-3. Epub 2017 Dec 7.

PMID:
29218652
8.

Editor's Highlight: PPARβ/δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis.

Borland MG, Yao PL, Kehres EM, Lee C, Pritzlaff AM, Ola E, Wagner AL, Shannon BE, Albrecht PP, Zhu B, Kang BH, Robertson GP, Gonzalez FJ, Peters JM.

Toxicol Sci. 2017 Oct 1;159(2):436-448. doi: 10.1093/toxsci/kfx147.

PMID:
28962521
9.

Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.

Kuzu OF, Gowda R, Sharma A, Noory MA, Kardos G, Madhunapantula SV, Drabick JJ, Robertson GP.

Cancer Biol Ther. 2018 Jan 2;19(1):53-62. doi: 10.1080/15384047.2017.1360446. Epub 2017 Nov 30.

PMID:
28853983
10.

Improving pharmacological targeting of AKT in melanoma.

Kuzu OF, Gowda R, Sharma A, Noory MA, Dinavahi SS, Kardos G, Drabick JJ, Robertson GP.

Cancer Lett. 2017 Sep 28;404:29-36. doi: 10.1016/j.canlet.2017.07.001. Epub 2017 Jul 11.

PMID:
28705772
11.

Modulating cancer cell survival by targeting intracellular cholesterol transport.

Kuzu OF, Gowda R, Noory MA, Robertson GP.

Br J Cancer. 2017 Aug 8;117(4):513-524. doi: 10.1038/bjc.2017.200. Epub 2017 Jul 11.

PMID:
28697173
12.

Targeting cholesterol transport in circulating melanoma cells to inhibit metastasis.

Chen YC, Gowda R, Newswanger RK, Leibich P, Fell B, Rosenberg G, Robertson GP.

Pigment Cell Melanoma Res. 2017 Jan;30(6):541-552. doi: 10.1111/pcmr.12614. Epub 2017 Oct 15.

PMID:
28685959
13.

Cellulosic biofuel contributions to a sustainable energy future: Choices and outcomes.

Robertson GP, Hamilton SK, Barham BL, Dale BE, Izaurralde RC, Jackson RD, Landis DA, Swinton SM, Thelen KD, Tiedje JM.

Science. 2017 Jun 30;356(6345). pii: eaal2324. doi: 10.1126/science.aal2324. Review.

PMID:
28663443
14.

Identifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol transport.

Gowda R, Inamdar GS, Kuzu O, Dinavahi SS, Krzeminski J, Battu MB, Voleti SR, Amin S, Robertson GP.

Oncotarget. 2017 Apr 25;8(17):28260-28277. doi: 10.18632/oncotarget.16002.

15.

Future of circulating tumor cells in the melanoma clinical and research laboratory settings.

De Souza LM, Robertson BM, Robertson GP.

Cancer Lett. 2017 Apr 28;392:60-70. doi: 10.1016/j.canlet.2017.01.023. Epub 2017 Feb 2. Review.

PMID:
28163189
16.

Field-scale experiments reveal persistent yield gaps in low-input and organic cropping systems.

Kravchenko AN, Snapp SS, Robertson GP.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):926-931. doi: 10.1073/pnas.1612311114. Epub 2017 Jan 17.

17.

Targeting protein kinase-b3 (akt3) signaling in melanoma.

Madhunapantula SV, Robertson GP.

Expert Opin Ther Targets. 2017 Mar;21(3):273-290. doi: 10.1080/14728222.2017.1279147. Epub 2017 Jan 16. Review.

PMID:
28064546
18.

Effect of lysosomotropic molecules on cellular homeostasis.

Kuzu OF, Toprak M, Noory MA, Robertson GP.

Pharmacol Res. 2017 Mar;117:177-184. doi: 10.1016/j.phrs.2016.12.021. Epub 2016 Dec 23. Review.

PMID:
28025106
19.

Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.

Gowda R, Kardos G, Sharma A, Singh S, Robertson GP.

Mol Cancer Ther. 2017 Mar;16(3):440-452. doi: 10.1158/1535-7163.MCT-16-0285. Epub 2016 Dec 21.

20.

Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.

Gowda R, Sharma A, Robertson GP.

Cancer Lett. 2017 Jan 28;385:243-250. doi: 10.1016/j.canlet.2016.10.016. Epub 2016 Oct 18.

PMID:
27769779
21.

Long-term nitrous oxide fluxes in annual and perennial agricultural and unmanaged ecosystems in the upper Midwest USA.

Gelfand I, Shcherbak I, Millar N, Kravchenko AN, Robertson GP.

Glob Chang Biol. 2016 Nov;22(11):3594-3607. doi: 10.1111/gcb.13426. Epub 2016 Aug 11.

PMID:
27510313
22.

The Role of Cholesterol in Cancer.

Kuzu OF, Noory MA, Robertson GP.

Cancer Res. 2016 Apr 15;76(8):2063-70. doi: 10.1158/0008-5472.CAN-15-2613. Epub 2016 Apr 5. Review.

23.

eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis.

Cheng Y, Ren X, Yuan Y, Shan Y, Li L, Chen X, Zhang L, Takahashi Y, Yang JW, Han B, Liao J, Li Y, Harvey H, Ryazanov A, Robertson GP, Wan G, Liu D, Chen AF, Tao Y, Yang JM.

Oncogene. 2016 Dec 8;35(49):6293-6308. doi: 10.1038/onc.2016.166. Epub 2016 May 16. Erratum in: Oncogene. 2018 Jul 4;:.

PMID:
27181208
24.

Climate-smart soils.

Paustian K, Lehmann J, Ogle S, Reay D, Robertson GP, Smith P.

Nature. 2016 Apr 7;532(7597):49-57. doi: 10.1038/nature17174.

PMID:
27078564
25.

Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy.

Brys AK, Gowda R, Loriaux DB, Robertson GP, Mosca PJ.

Biotechnol Adv. 2016 Sep-Oct;34(5):565-577. doi: 10.1016/j.biotechadv.2016.01.004. Epub 2016 Jan 28. Review.

PMID:
26826558
26.

Topography Mediates the Influence of Cover Crops on Soil Nitrate Levels in Row Crop Agricultural Systems.

Ladoni M, Kravchenko AN, Robertson GP.

PLoS One. 2015 Nov 23;10(11):e0143358. doi: 10.1371/journal.pone.0143358. eCollection 2015.

27.

Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.

Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, Schjerven H, Muschen M, Payne KJ, Dovat S.

Blood. 2015 Oct 8;126(15):1813-22. doi: 10.1182/blood-2015-06-651505. Epub 2015 Jul 28.

28.

Therapeutic interventions to disrupt the protein synthetic machinery in melanoma.

Kardos GR, Robertson GP.

Pigment Cell Melanoma Res. 2015 Sep;28(5):501-19. doi: 10.1111/pcmr.12391. Review.

29.

Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway.

Kardos GR, Wastyk HC, Robertson GP.

Mol Cancer Res. 2015 Oct;13(10):1408-20. doi: 10.1158/1541-7786.MCR-15-0048. Epub 2015 Jun 16.

30.

Can Impacts of Climate Change and Agricultural Adaptation Strategies Be Accurately Quantified if Crop Models Are Annually Re-Initialized?

Basso B, Hyndman DW, Kendall AD, Grace PR, Robertson GP.

PLoS One. 2015 Jun 4;10(6):e0127333. doi: 10.1371/journal.pone.0127333. eCollection 2015.

31.

A non-cytotoxic N-dehydroabietylamine derivative with potent antimalarial activity.

Sadashiva MP, Gowda R, Wu X, Inamdar GS, Kuzu OF, Rangappa KS, Robertson GP, Gowda DC.

Exp Parasitol. 2015 Aug;155:68-73. doi: 10.1016/j.exppara.2015.05.002. Epub 2015 May 14.

32.

Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.

Gowda R, Madhunapantula SV, Sharma A, Kuzu OF, Robertson GP.

Mol Cancer Ther. 2014 Oct;13(10):2328-40. doi: 10.1158/1535-7163.MCT-14-0357. Epub 2014 Jul 31.

33.

Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.

Gowda R, Jones NR, Banerjee S, Robertson GP.

J Nanomed Nanotechnol. 2013 Dec;4(6). pii: 184.

34.

Global metaanalysis of the nonlinear response of soil nitrous oxide (N2O) emissions to fertilizer nitrogen.

Shcherbak I, Millar N, Robertson GP.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9199-204. doi: 10.1073/pnas.1322434111. Epub 2014 Jun 9. Review.

35.

Growth inhibitory effects of large subunit ribosomal proteins in melanoma.

Kardos GR, Dai MS, Robertson GP.

Pigment Cell Melanoma Res. 2014 Sep;27(5):801-12. doi: 10.1111/pcmr.12259. Epub 2014 Jun 16.

36.

Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport.

Kuzu OF, Gowda R, Sharma A, Robertson GP.

Mol Cancer Ther. 2014 Jul;13(7):1690-703. doi: 10.1158/1535-7163.MCT-13-0868. Epub 2014 Mar 31.

37.

Targeting multiple key signaling pathways in melanoma using leelamine.

Gowda R, Madhunapantula SV, Kuzu OF, Sharma A, Robertson GP.

Mol Cancer Ther. 2014 Jul;13(7):1679-89. doi: 10.1158/1535-7163.MCT-13-0867. Epub 2014 Mar 31.

38.

Perennial grasslands enhance biodiversity and multiple ecosystem services in bioenergy landscapes.

Werling BP, Dickson TL, Isaacs R, Gaines H, Gratton C, Gross KL, Liere H, Malmstrom CM, Meehan TD, Ruan L, Robertson BA, Robertson GP, Schmidt TM, Schrotenboer AC, Teal TK, Wilson JK, Landis DA.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1652-7. doi: 10.1073/pnas.1309492111. Epub 2014 Jan 13.

39.

Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.

Dluzen DF, Sun D, Salzberg AC, Jones N, Bushey RT, Robertson GP, Lazarus P.

J Pharmacol Exp Ther. 2014 Mar;348(3):465-77. doi: 10.1124/jpet.113.210658. Epub 2014 Jan 7.

40.

Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential.

Mumford BS, Robertson GP.

Mol Diagn Ther. 2014 Apr;18(2):175-83. doi: 10.1007/s40291-013-0071-2. Review.

41.

Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.

Madhunapantula SV, Sharma A, Gowda R, Robertson GP.

Pigment Cell Melanoma Res. 2013 Nov;26(6):886-99. doi: 10.1111/pcmr.12156. Epub 2013 Sep 19.

42.

CD82/KAI expression prevents IL-8-mediated endothelial gap formation in late-stage melanomas.

Khanna P, Chung CY, Neves RI, Robertson GP, Dong C.

Oncogene. 2014 May 29;33(22):2898-908. doi: 10.1038/onc.2013.249. Epub 2013 Jul 22.

PMID:
23873025
43.

Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.

Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP, Huang L.

Mol Ther. 2013 Oct;21(10):1919-29. doi: 10.1038/mt.2013.135. Epub 2013 Jun 18.

44.

Predicting therapy response in live tumor cells isolated with the flexible micro spring array device.

Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, Yang Z, Harvey HA, Cream LV, Kumar SM, Robertson GP, Zheng S, Drabick JJ, Truica CI, El-Deiry WS.

Cell Cycle. 2013 Jul 1;12(13):2132-43. doi: 10.4161/cc.25165. Epub 2013 Jun 11.

45.

Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP.

Am J Pathol. 2013 Apr;182(4):1151-62. doi: 10.1016/j.ajpath.2012.12.019. Epub 2013 Feb 12.

46.

Sustainable bioenergy production from marginal lands in the US Midwest.

Gelfand I, Sahajpal R, Zhang X, Izaurralde RC, Gross KL, Robertson GP.

Nature. 2013 Jan 24;493(7433):514-7. doi: 10.1038/nature11811. Epub 2013 Jan 16.

PMID:
23334409
47.

Current and future trials of targeted therapies in cutaneous melanoma.

Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ.

Adv Exp Med Biol. 2013;779:223-55. doi: 10.1007/978-1-4614-6176-0_10. Review.

48.

Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns.

Singh S, Sharma A, Robertson GP.

Cancer Res. 2012 Nov 15;72(22):5663-8. doi: 10.1158/0008-5472.CAN-12-1527. Epub 2012 Nov 8. Review.

49.

Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.

Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP.

Mol Cancer Ther. 2013 Jan;12(1):3-15. doi: 10.1158/1535-7163.MCT-12-0492. Epub 2012 Oct 30.

50.

Chemoprevention of melanoma.

Madhunapantula SV, Robertson GP.

Adv Pharmacol. 2012;65:361-98. doi: 10.1016/B978-0-12-397927-8.00012-9. Review.

Supplemental Content

Loading ...
Support Center